Agentix Corp.
- Tickers
- AGTX
- Headquarters
- Not recorded
- SEC CIK
- 0001603345
- Website
- Not recorded
Closing prices
No closing prices are stored for AGTX yet. They arrive with the weekly end-of-day update.
Drugs
No drugs from this company are tracked yet.
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 0 USD | 1 Apr 2022 to 31 Mar 2023 FY2023 | 10-K for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −117,674 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 16,635 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 95,504 USD | 1 Apr 2026 to 30 Jun 2026 FY2027 Q1 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 38 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 3,713,831 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −3,713,793 USD | At 30 Jun 2026 FY2027 Q1 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 40,066,951 shares | At 7 Aug 2026 FY2027 Q1 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Apr 2022 to 31 Mar 2023 FY2023 | 0 USD | 10-K filed 14 Jul 2023 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2022 to 31 Dec 2022 FY2023 Q3 | 0 USD | 10-Q filed 14 Feb 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2022 to 30 Sep 2022 FY2023 Q2 | 0 USD | 10-Q filed 14 Nov 2022 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2021 to 31 Mar 2022 FY2023 | 1,240 USD | 10-K filed 14 Jul 2023 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2021 to 31 Dec 2021 FY2023 Q3 | 0 USD | 10-Q filed 14 Feb 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2021 to 30 Sep 2021 FY2023 Q2 | 1,240 USD | 10-Q filed 14 Nov 2022 on sec.gov (opens in a new tab)Filed |
| 1 Mar 2021 to 31 May 2021 FY2021 Q3 | 0 USD | 10-Q filed 9 Jul 2021 on sec.gov (opens in a new tab)Filed |
| 1 Dec 2020 to 28 Feb 2021 FY2021 Q2 | 0 USD | 10-Q filed 29 Mar 2021 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Agentix Corp. on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.